Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS11D | O60235 | 12/20 | 0.44 |
| ▸ | F2 | P00734 | 7/20 | 0.44 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | PLG | P00747 | 3/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48899 | 0.80 | CA12 (0.38) | F10PLG | |
| SCHEMBL1416490 | 0.79 | TMPRSS11D (0.61) | TMPRSS11DF2F10PLG | |
| SCHEMBL2997234 | 0.79 | DPP4 (0.47) | F2FKBP1ADPP4DPP8DPP9 | |
| SCHEMBL31206155 | 0.74 | OPRM1 (0.54) | F2PLG | |
| SCHEMBL49084 | 0.74 | TMPRSS11D (0.73) | TMPRSS11DF2F10PLG | |
| SCHEMBL7343548 | 0.73 | DPP4 (0.53) | F2FKBP1ADPP4DPP8DPP9 | |
| SCHEMBL7343558 | 0.73 | DPP4 (0.53) | F2FKBP1ADPP4DPP8DPP9 | |
| Sulfuric Acid SCHEMBL9733221 | 0.72 | DPP4 (0.45) | F2F10PLGDPP4DPP8 | |
| SCHEMBL10901745 | 0.72 | OPRM1 (0.51) | F2 | |
| SCHEMBL6850160 | 0.71 | F2 (0.57) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129547-B2 | Anticoagulation of human blood ex vivo | HELLSTERN PETER (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | HELLSTERN PETER | 2010-11-04 | — | — | US | disclosed |
| EP-1973929-B1 | ANTICOAGULATION OF HUMAN BLOOD EX VIVO | HELLSTERN PETER (DE) | 2010-09-29 | — | — | EP | disclosed |
| EP-1973929-A2 | ANTICOAGULATION OF HUMAN BLOOD EX VIVO | Hellstern, Peter (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007085461-A2 | ANTICOAGULATION OF HUMAN BLOOD EX VIVO | STÜRZEBECHER, Uta (DE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | F5, TFPI, F11 | TMPRSS11D 496/4885F2 13/4885F10 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.